A Triazolotriazine-Based Dual GSK-3 beta /CK-1 delta Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition.
Redenti, S., Marcovich, I., De Vita, T., Perez, C., De Zorzi, R., Demitri, N., Perez, D.I., Bottegoni, G., Bisignano, P., Bissaro, M., Moro, S., Martinez, A., Storici, P., Spalluto, G., Cavalli, A., Federico, S.(2019) ChemMedChem 14: 310-314
- PubMed: 30548443 
- DOI: 10.1002/cmdc.201800778
- Primary Citation of Related Structures:  
6H0U - PubMed Abstract: 
Glycogen synthase kinase 3β (GSK-3β) and casein kinase 1δ (CK-1δ) are emerging targets for the treatment of neuroinflammatory disorders, including Parkinson's disease. An inhibitor able to target these two kinases was developed by docking-based design. Compound 12, 3-(7-amino-5-(cyclohexylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl)-2-cyanoacrylamide, showed combined inhibitory activity against GSK-3β and CK-1δ [IC 50 (GSK-3β)=0 ...